MARIA RODINO, MD
Endocrinology, Diabetes & Metabolism Physician in WESTWOOD, New Jersey. CMS National Plan and Provider Enumeration System profile including specialty classification, practice address, and Medicare prescribing data when reported.
What the federal data shows
MARIA RODINO, MD filed 1,621 Medicare Part D claims in 2023 as a Endocrinology, Diabetes & Metabolism Physician in WESTWOOD, New Jersey, prescribing 52% generic.
- 2K
- Part D claims, 2023
- 52%
- generic prescribing
- $367.23
- industry payments (Sunshine Act)
Every figure on this page comes straight from federal CMS records (NPPES, Medicare Part D, MIPS, Open Payments) — no proprietary rating or editorial opinion is applied.
MARIA RODINO, MD's Medicare Part D volume vs every U.S. prescriber
Total Medicare Part D claims, 2023 — across all CMS prescribers nationally
1,621 Top 18% higher than 82% of 1,370,886 prescribers
Each bar is a band; taller bars hold more prescribers. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count, share, and where it sits relative to this entry.
Source CMS Medicare Part D Prescriber Public Use File · 2023
MARIA RODINO, MD practices in an ABMS-board-eligible specialty but we don't have enough CMS-participation signals to confirm active board-certified status. Consult CertificationMatters.org (the official ABMS public lookup).
What does the federal data show about MARIA RODINO, MD?
Quality data not reportedPrimary specialty
Medicare Part D claims
Specialty distribution in New Jersey
How Endocrinology, Diabetes & Metabolism Physician compares to other specialties among New Jersey providers
Endocrinology, Diabetes & Metabolism Physician share within New Jersey
Endocrinology, Diabetes & Metabolism Physician is one of the more visible NUCC categories in New Jersey
Each bar reflects the share of in-state providers whose primary NUCC taxonomy matches the specialty. Long tail of ~690 NUCC codes folded into "Other" to keep the comparison legible.
Specialty board-certification context
Estimated specialty board-certified rate — Endocrinology, Diabetes & Metabolism Physician (ABMS / AOA reference)
- Est. board-certified rate
- 78%
- Endocrinology, Diabetes & Metabolism Physician ABMS/AOA estimate
Est. board-certified rate (Endocrinology, Diabetes & Metabolism Physician) — ABMS / AOA estimate
Verify credentials
- Verify via ABMS free public lookup
- Verify via AOA osteopathic boards
- Specialty volume Endocrinology, Diabetes & Metabolism Physician US NPIs
Specialty board-certified rate — Endocrinology, Diabetes & Metabolism Physician estimate
Board certification through an ABMS or AOA member board signals voluntary post-licensure examination plus Maintenance of Certification cycles. CMS does not publish a per-provider board-certification field; the figure shown is the specialty-level estimated rate from ABMS / AOA reference data.
The Merit-based Incentive Payment System (MIPS) scores providers 0–100 across four performance categories: Quality, Cost, Promoting Interoperability, and Improvement Activities, weighted under 42 CFR §414.1380. Reporting is voluntary for many small practices, so absence of a MIPS score is not a quality signal.
Board certification through an ABMS or AOA member board signals voluntary post-licensure examination plus continuous Maintenance of Certification cycles. Verify any individual provider's status through certificationmatters.org (ABMS) or osteopathic.org (AOA).
MARIA RODINO, MD appears in the CMS NPPES registry as a Endocrinology, Diabetes & Metabolism Physician provider holding MD credentials at 219 OLD HOOK RD, WESTWOOD, NJ, 07675, with a listed phone of (201) 722-0600. NPI 1497820906 was issued on 11/21/2006. Because NPPES data is self-reported by the provider and refreshed monthly, the address, phone, and specialty reflect what RODINO most recently submitted to CMS rather than a vetted directory listing, which is why patients should always confirm the practice is still at this location before scheduling.
Medicare Part D records for calendar year 2023 show 1,621 prescription claims written by this provider, covering 201 Medicare beneficiaries and totaling roughly $547K in drug spend, split 48% brand-name and 52% generic by claim count. These figures capture only Medicare Part D — commercial insurance, Medicaid, and cash-pay prescriptions are not included, and any drug-beneficiary cell under 11 is suppressed by CMS for patient privacy.
Endocrinology, Diabetes & Metabolism Physician is a mid-sized specialty nationwide, with 7,852 enrolled providers across 54 states and an average of 2,639 Part D claims per prescriber, so the context for interpreting these metrics differs meaningfully from a primary-care baseline. Important: PlainDoctor is a directory of publicly available government data, not medical advice, a malpractice database, or a quality rating. Inclusion here does not imply a recommendation, and absence of complaints or sanctions on this page does not mean none exist — always verify credentials through the NPPES NPI Registry, your state medical board, and the ABMS or AOA before making healthcare decisions.
Practice Address
Provider Details
| NPI | 1497820906 |
|---|---|
| Specialty | Endocrinology, Diabetes & Metabolism Physician |
| Credentials | MD |
| Gender | Female |
| NPI Issued | 11/21/2006 |
Verify this provider's license
PlainDoctor pulls this profile from the CMS NPPES public registry. Confirm MARIA RODINO, MD's current license status, disciplinary history, and board certifications with the New Jersey State Board of Medical Examiners in New Jersey before relying on this page for a clinical or care decision.
How we sourced this profile
Industry payments received (2024) — CMS Open Payments transparency data
The federal Physician Payments Sunshine Act (part of the Affordable Care Act) requires drug and medical-device manufacturers + group purchasing organizations to publicly report payments and other transfers of value to physicians and teaching hospitals. The data below covers 2024 for MARIA RODINO, MD. Source: openpaymentsdata.cms.gov.
Total received
$367
Largest payer
Amgen Inc.
Most common payment type
Food and Beverage
Industry payments are not necessarily indicators of bias — they include research funding, consulting fees for evidence-based work, royalties for inventions, food at conferences, and similar items. The disclosure exists for transparency. Read our methodology for how we interpret this data.
Brand vs generic prescribing mix · Above average
48% brand-name claims vs 52% generic, on 1,621 2023 Medicare Part D claims.
The federal Medicare Part D Generic Dispensing Rate national benchmark sits near 90% generic / 10% brand for primary-care prescribers, per CMS Office of the Actuary 2024 estimates. Higher brand share is common in specialty prescribing where generic equivalents are not available.
Medicare Part D Prescribing Data
CMS Medicare Part D prescriber-level data for calendar year 2023.
Prescribing Breakdown
- 30-Day Fills
- 4,253
- Total Day Supply
- 127,396
- Brand vs Generic
- 48% brand / 52% generic
- Brand Drug Cost
- $513K
- Generic Drug Cost
- $31K
Patient Demographics
- Average Patient Age
- 75.3 years
- Avg HCC Risk Score
- 1.13
- Gender Split
- 80% female / 20% male
Top Prescribed Drugs (Medicare Part D)
Top drugs by claim count for calendar year 2023. Based on Medicare Part D data only.
What MARIA RODINO, MD prescribes most
Top Medicare Part D drugs by claim count, 2023
- Levothyroxine Sodium
Levothyroxine Sodium
323 claims
- Synthroid
Synthroid
217 claims
- Metformin Hcl Er
Metformin Hcl Er
161 claims
- Atorvastatin Calcium 75
Atorvastatin Calcium
75 claims
- Rosuvastatin Calcium 70
Rosuvastatin Calcium
70 claims
- Farxiga 61
Farxiga
61 claims
- Ozempic 58
Ozempic
58 claims
- Alendronate Sodium 43
Alendronate Sodium
43 claims
| Drug | Claims |
|---|---|
| Levothyroxine Sodium | 323 |
| Synthroid Levothyroxine Sodium | 217 |
| Metformin Hcl Er Metformin Hcl | 161 |
| Atorvastatin Calcium | 75 |
| Rosuvastatin Calcium | 70 |
| Farxiga Dapagliflozin Propanediol | 61 |
| Ozempic Semaglutide | 58 |
| Alendronate Sodium | 43 |
| Jardiance Empagliflozin | 42 |
| Losartan Potassium | 33 |
* Counts below 11 are suppressed by CMS for patient privacy. Generic names shown where available from CMS Part D data.
Endocrinology, Diabetes & Metabolism Physician Overview
How MARIA RODINO, MD fits within the Endocrinology, Diabetes & Metabolism Physician landscape nationally.
MARIA RODINO, MD's 1,621 claims are below the specialty average of 2,639.
Nearby Endocrinology, Diabetes & Metabolism Physician Providers in New Jersey
Other clinicians with the same primary specialty enrolled in New Jersey, drawn from the same CMS NPPES roster as RODINO.
Compare Endocrinology, Diabetes & Metabolism Physician nationally: see state-by-state distribution →
Healthcare Guides
Learn more about finding, verifying, and understanding healthcare providers.
Explore New Jersey
Frequently Asked Questions
What is MARIA RODINO, MD's specialty? ▼
How much does MARIA RODINO, MD prescribe under Medicare Part D? ▼
Where is MARIA RODINO, MD located? ▼
What is MARIA RODINO, MD's NPI number? ▼
Does MARIA RODINO, MD prescribe more brand-name or generic drugs? ▼
How many Endocrinology, Diabetes & Metabolism Physician providers are there in the US? ▼
What drugs does MARIA RODINO, MD prescribe most often? ▼
Does MARIA RODINO, MD accept Medicare? ▼
How can I verify MARIA RODINO, MD's credentials? ▼
Data Sources
- Provider Directory
- CMS National Plan and Provider Enumeration System (NPPES), download.cms.gov/nppes, updated monthly. Contains NPI, specialty, credentials, and practice location.
- Specialty Classification
- NUCC Health Care Provider Taxonomy (nucc.org), the industry standard for classifying provider specialties in Medicare and Medicaid billing.
- Prescribing Data
- CMS Medicare Part D Prescriber Public Use File (2023). Includes claims, drug costs, beneficiaries, and opioid prescribing rates.
- Limitations
- Provider data is self-reported to CMS. Prescribing data reflects Medicare Part D only and does not include commercial insurance, Medicaid, or cash prescriptions. Claims below 11 beneficiaries are suppressed by CMS for privacy.
See our complete data methodology for details on how we collect and process government data.
Data as of April 2026 (NPPES) / 2023 (Medicare Part D). Source: Centers for Medicare & Medicaid Services (CMS).
Disclaimer: Data from CMS NPPES and Medicare Part D. PlainDoctor does not rate or rank providers. Provider information is self-reported and may not be current. Always verify information directly with the provider. About · Methodology